Results: 2

1.
Figure 2

Figure 2. Kaplan-Meier Estimates of Probability of Remaining Free of CMV Infection. From: Vaccine Prevention of Maternal Cytomegalovirus Infection.

Up to 42 months after study enrollment, subjects in the vaccine group were more likely to remain free of CMV infection than were subjects in the placebo group (P = 0.02). In the vaccine group, 18 subjects were found to have CMV infection, as compared with 31 in the placebo group.

Robert F. Pass, et al. N Engl J Med. ;360(12):1191-1199.
2.
Figure 1

Figure 1. Enrollment and Outcomes. From: Vaccine Prevention of Maternal Cytomegalovirus Infection.

In the vaccine group, 47 subjects did not receive the full three doses of vaccine because 4 were lost to follow-up, 5 had an adverse event, 7 had a compliance issue, 5 withdrew from the study, 2 were found to have CMV infection, 6 became pregnant, and 18 were unable to receive the vaccine owing to its unavailability. In the placebo group, 60 subjects did not receive three doses of placebo because 16 were lost to follow-up, 2 had an adverse event, 4 had a compliance issue, 4 withdrew from the study, 4 were found to have CMV infection, 13 became pregnant, and 17 were unable to receive placebo owing to its unavailability.

Robert F. Pass, et al. N Engl J Med. ;360(12):1191-1199.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk